검색
Adaptimmune Therapeutics PLC
ADAP관심 목록에 추가
0.055USD
0.0000.00%
종가 07/02, 13:00（ET）시세는 15분 지연됩니다
10.34M시가총액
손실P/E TTM
자세한 내용은 Adaptimmune Therapeutics PLC 회사
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Adaptimmune Therapeutics PLC 정보
종목 코드 ADAP
회사 이름Adaptimmune Therapeutics PLC
상장일May 06, 2015
CEORawcliffe (Adrian George)
직원 수506
유형Depository Receipt
회계 연도 종료May 06
주소60 Jubilee Avenue
도시ABINGDON
증권 거래소NASDAQ Capital Market Consolidated
국가United Kingdom
우편 번호OX14 4RX
전화441235430000
웹사이트https://www.adaptimmune.com/
종목 코드 ADAP
상장일May 06, 2015
CEORawcliffe (Adrian George)
Adaptimmune Therapeutics PLC의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Priti Hegde, Ph.D.
Dr. Priti Hegde, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
자주 묻는 질문
Adaptimmune Therapeutics PLC의 상위 5대 주주는 누구인가요?
Adaptimmune Therapeutics PLC의 상위 5대 주주는 다음과 같습니다: Dr. Garry E. Menzel, Ph.D.
Adaptimmune Therapeutics PLC(ADAP)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Adaptimmune Therapeutics PLC의 주식을 보유한 기관은 총 159곳이며, 이들이 보유한 주식의 총 가치는 약 1.79M로 전체 발행 주식의 0.67%를 차지합니다. 이는 2025Q4 대비 -156325066.00 증가한 수치입니다.